Investment analysts at Guggenheim started coverage on shares of Curis, Inc. (NASDAQ:CRIS) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.

CRIS has been the topic of several other reports. Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. ValuEngine cut Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, BidaskClub upgraded Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $6.00.

Shares of Curis (NASDAQ:CRIS) remained flat at $1.57 on Monday. 729,679 shares of the stock traded hands. The firm’s 50-day moving average is $1.73 and its 200 day moving average is $1.92. Curis has a one year low of $1.47 and a one year high of $3.72. The firm’s market capitalization is $225.89 million.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). The firm had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) earnings per share. Equities research analysts anticipate that Curis will post ($0.40) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Curis, Inc. (CRIS) Coverage Initiated by Analysts at Guggenheim” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/curis-inc-cris-coverage-initiated-by-analysts-at-guggenheim.html.

Several institutional investors have recently bought and sold shares of CRIS. Prudential Financial Inc. bought a new position in shares of Curis during the 1st quarter worth approximately $105,000. American International Group Inc. raised its position in shares of Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 4,560 shares during the period. FMR LLC raised its position in shares of Curis by 2.7% during the first quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock worth $42,067,000 after purchasing an additional 393,582 shares during the period. Vanguard Group Inc. raised its position in shares of Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after purchasing an additional 304,268 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Curis by 8.3% during the first quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock worth $2,553,000 after purchasing an additional 70,139 shares during the period. Hedge funds and other institutional investors own 44.72% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

The Fly

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.